Compare Oatly Group AB - ADR (OTLY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

OTLY trades at $10.37, down 1.33% today, with mixed technical signals showing bearish moving averages but bullish oscillators. The company reported Q2 2026 revenue growth and raised full-year guidance, though it continues to post significant net losses. Analyst sentiment is divided with a $12.28 consensus price target representing 18% upside potential. Cash flow remains negative but improving, with operating losses narrowing from -$269M in 2022 to -$24M in 2025.

The investment case hinges on OTLY's revenue growth acceleration and path to profitability, but high debt levels and persistent losses present substantial risk. While the stock offers potential upside to analyst targets, investors must weigh the company's improving operational trends against its negative equity and cash burn. The upcoming Q3 2026 earnings report on October 28 will be critical for validating management's turnaround narrative.

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.